Subacromial impingement syndrome and pain: protocol for a randomised controlled trial of exercise and corticosteroid injection (the SUPPORT trial) by Edward Roddy et al.
Roddy et al. BMC Musculoskeletal Disorders 2014, 15:81
http://www.biomedcentral.com/1471-2474/15/81STUDY PROTOCOL Open AccessSubacromial impingement syndrome and pain:
protocol for a randomised controlled trial of
exercise and corticosteroid injection
(the SUPPORT trial)
Edward Roddy1,2*, Irena Zwierska1, Elaine M Hay1,2, Sue Jowett1, Martyn Lewis1, Kay Stevenson1,2,3,
Danielle van der Windt1, Nadine E Foster1 and the SUPPORT trial teamAbstract
Background: Subacromial impingement syndrome is the most frequent cause of shoulder problems which
themselves affect 1 in 3 adults. Management commonly includes exercise and corticosteroid injection. However, the
few existing trials of exercise or corticosteroid injection for subacromial impingement syndrome are mostly small, of
poor quality, and focus only on short-term results. Exercise packages tend to be standardised rather than individua-
lised and progressed. There has been much recent interest in improving outcome from corticosteroid injections by
using musculoskeletal ultrasound to guide injections. However, there are no high-quality trials comparing
ultrasound-guided and blind corticosteroid injection in subacromial impingement syndrome. This trial will investi-
gate how to optimise the outcome of subacromial impingement syndrome from exercise (standardised advice and
information leaflet versus physiotherapist-led exercise) and from subacromial corticosteroid injection (blind versus
ultrasound-guided), and provide long-term follow-up data on clinical and cost-effectiveness.
Methods/Design: The study design is a 2x2 factorial randomised controlled trial. 252 adults with subacromial
impingement syndrome will be recruited from two musculoskeletal Clinical Assessment and Treatment Services at
the primary-secondary care interface in Staffordshire, UK. Participants will be randomised on a 1:1:1:1 basis to one of
four treatment groups: (1) ultrasound-guided subacromial corticosteroid injection and a physiotherapist-led exercise
programme, (2) ultrasound-guided subacromial corticosteroid injection and an advice and exercise leaflet, (3) blind
subacromial corticosteroid injection and a physiotherapist-led exercise programme, or (4) blind subacromial cortico-
steroid injection and an advice and exercise leaflet. The primary intention-to-treat analysis will be the mean differ-
ences in Shoulder Pain and Disability Index (SPADI) scores at 6 weeks for the comparison between injection
interventions and at 6 months for the comparison between exercise interventions. Although independence of treat-
ment effects is assumed, the magnitude of any interaction effect will be examined (but is not intended for the main
analyses). Secondary outcomes will include comparison of long-term outcomes (12 months) and cost-effectiveness.
A secondary per protocol analysis will also be performed.
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Discussion: This protocol paper presents detail of the rationale, design, methods and operational aspects of the
SUPPORT trial.
Trial registration: Current controlled trials ISRCTN42399123.
Keywords: Subacromial impingement syndrome, Shoulder pain, Randomised controlled trial, Corticosteroid
injection, Musculoskeletal ultrasound, Exercise, PhysiotherapyBackground
Painful shoulder problems are a common cause of im-
paired function and affect 1 in 3 adults [1,2], accounting
for 1% of general practice (GP) consultations [3]. Suba-
cromial impingement syndrome (SIS) is the most com-
mon cause of shoulder pain and affects approximately
one-half of all shoulder pain sufferers [3]. SIS typically
presents with pain during elevation of the arm, when a
reduction in the space between the coracoacromial arch
of the scapula and the humerus causes pinching of the
subacromial/subdeltoid bursae, rotator cuff tendons and
long head of biceps [4]. SIS is thought to arise as a result
of bony abnormalities, rotator cuff weakness, impaired
scapulohumeral rhythm, scapular instability and poor
posture [4,5]. Treatment aims to reduce pain and in-
crease function and UK management guidelines recom-
mend exercise and corticosteroid injection in addition
to patient education, oral analgesia and application of
ice-packs [4,6]. In our recent observational study of
patient outcome from treatment in primary-secondary
care interface musculoskeletal clinics, 46% of patients
with SIS received a corticosteroid injection and 38%
were referred to a physiotherapist [7].
Exercise aims to reduce pain and functional impair-
ment by improving posture, muscle strength, scapular
stability and scapulohumeral rhythm [8]. It can be indivi-
dualised, progressed and supervised by physiotherapists or
self-guided from a leaflet containing standardised exer-
cises [9]. Recent systematic reviews of exercise in SIS con-
cluded that exercise decreases pain and improves function
but that most trials are small, of poor quality, focus on
short-term results only, and provide insufficient detail to
allow firm conclusions to be drawn about the type, inten-
sity, frequency and duration of exercise which is associ-
ated with best outcomes [10,11]. Consensus-based clinical
guidelines recommend a ‘core’ set of exercises for SIS [4].
Studies in other musculoskeletal conditions support in-
dividualised, supervised and progressed exercise rather
than a standard exercise approach [12] but, to date,
there are few trials to guide exercise practice for pa-
tients with SIS [13-15].
Corticosteroid injections are commonly used to reduce
pain and inflammation associated with SIS [16] although
there is debate about their efficacy. Previous trials sug-
gest similar effectiveness of corticosteroid injection andphysiotherapy for both mixed shoulder problems [17,18]
and SIS [19] whereas other trials report short-term super-
iority of injection over physiotherapy for mixed shoulder
problems which is lost in the long-term [20,21]. A recent
trial compared subacromial corticosteroid injection com-
bined with exercise and manual therapy versus exercise
and manual therapy alone for SIS and found similar im-
provements in pain and function at 3 months, however,
more rapid reduction in pain and disability was seen in
the group that received an injection [14]. These trials
all used ‘blind’ shoulder injection, where the site of in-
jection is located by observation and palpation. Poor re-
sponse to blind injection has been attributed to misplaced
injection [22-24].
Musculoskeletal ultrasound (MSUS) has become an in-
creasingly accepted tool for guidance of therapeutic inter-
ventions [25,26]. However, although MSUS is low cost,
can be carried out as a ‘bed-side’ procedure and has high
resolution [26], few studies of ultrasound-guided (US-
guided) injection for shoulder pain have been conducted.
A recent RCT compared US-guided subacromial cortico-
steroid injection with systemic corticosteroid injection in
patients with rotator cuff disease and found no difference
in shoulder pain and function between groups at six weeks
[27]. US-guided corticosteroid injection is suggested to
provide greater improvements in pain, function and range
of movement than blind injection for the treatment of SIS
[28-30]. However, existing studies are small, of short dur-
ation, or are non-randomised, and none have originated
from the UK [24,28-31].
The evidence supports the need for a high quality trial
to determine how to optimise treatments for SIS pa-
tients and to reflect the complementary ways in which
these interventions are used clinically i.e. that exercise
and injection are often combined within the same pack-
age of care. The primary objectives of the SUPPORT trial
(SUbacromial imPingement syndrome and Pain: a rando-
mised controlled trial Of exeRcise and injecTion) are to
assess whether (1) a physiotherapist-led intervention con-
sisting of individualised, supervised and progressed exer-
cise provides better improvements in pain and function
than a standardised advice and exercise leaflet, and (2)
US-guided subacromial corticosteroid injection provides
better improvements in pain and function than unguided
(blind) injection. Secondary objectives are to determine
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guided injection and an individualised, supervised and
progressed exercise programme and to conduct two separ-
ate cost-effectiveness analyses for the comparisons out-
lined in (1) and (2).
Methods/Design
Study design
The study will be a 2×2 factorial randomised con-
trolled trial (Figure 1). Ethical approval has been obtained
from The Black Country Research Ethics Committee
(10/H1202/72).
Setting
Patients will be recruited through musculoskeletal inter-
face clinics in Staffordshire and Stoke-on-Trent Partner-
ship Trust. These services incorporate early referral to,
and rapid assessment by, specialist clinicians (rheuma-
tologists, rehabilitation medicine specialists, extended
scope physiotherapists and general practitioners with a
special interest (GPwSI)) within a multidisciplinary team-
working environment. Local family practices will be in-
formed about the trial.
Participants
Consecutive patients referred from primary care to in-
terface shoulder clinics will be assessed for eligibility by
interface clinicians.
Inclusion criteria
 18 years and over
 No history of significant shoulder trauma, for example,
fracture, clinically-suspected full thickness cuff tearFigure 1 Flow of participants through trial. A clinical diagnosis of SIS (pain in deltoid insertion
area, positive Neer and Hawkins-Kennedy tests, pain
on shoulder abduction).
Accurate diagnosis of SIS is challenging but combin-
ation of the patients’ history and response to Neer and
Hawkins-Kennedy tests (to rule SIS out with a negative
test) and pain on shoulder abduction (to rule SIS in with a
positive test) provides optimal sensitivity and specificity
[5]. Patients will not be required to undergo diagnostic
imaging (eg MRI) to reflect current practice where treat-
ment choices are informed by clinical findings.
Exclusion criteria
 Below 18 years old
 Those whose main complaint is due to neck
problems, acromioclavicular pathology, or other
primary shoulder disorders including adhesive
capsulitis or clinically-suspected full thickness
cuff tear
 Potentially serious pathology (inflammatory arthritis,
polymyalgia rheumatica, malignancy etc) or
ipsilateral shoulder surgery/replacement
 Those already on a surgical waiting list for shoulder
surgery
 Contra-indications to local corticosteroid injection
(known blood coagulation disorders, warfarin
therapy)
 Participation in a shoulder-focused exercise
programme or shoulder injection in the last month
 Inability to provide informed consent, complete
written questionnaires, or read instruction leaflets
written in English
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All patients referred to musculoskeletal interface services
at each site with shoulder pain, identified from the refer-
ral letter from primary care, will be triaged to an inter-
face service shoulder clinic. One to two weeks prior to
their appointment in the interface service shoulder clinic
all patients will be sent a letter of invitation and a Par-
ticipant Information Sheet (PIS).
Interface service shoulder clinic
Patients will attend for their routine clinic appointment,
according to normal NHS clinical attendance procedures.
The interface clinician will undertake the clinical consult-
ation according to usual practice. Patients who fulfil the
criteria for a diagnosis of SIS will be asked by the interface
clinician if they wish to be considered for trial partici-
pation. Patients who are interested in trial participation
will be invited by the interface clinician to see a Research
Nurse, who will further confirm eligibility and explain the
trial in full. Ineligible patients and those who do not wish
to participate in the trial will receive normal clinical care
delivered by the interface clinician according to usual
practice. Anonymised age and gender will be collected for
those patients who decline to take part, in order to assess
the external validity of the recruited sample of patients.
Eligible patients who are interested in the trial will be
asked by the Research Nurse to provide written in-
formed consent to participate. The Research Nurse will
allocate the participant a unique study number. The par-
ticipant will then complete a baseline questionnaire
(Table 1). The Research Nurse will check the baseline
questionnaire for completeness, before the participant is
randomised.
Randomisation
As the Research Nurse will remain blinded to treatment
allocation, a trial administrator in the interface service
shoulder clinic will organise the randomisation, using
Keele University’s Clinical Trial Unit’s telephone ran-
domisation service, and then inform participants of their
treatment allocation. Participants will be randomly allo-
cated in a 1:1:1:1 ratio to 1 of 4 treatment groups using
block randomisation to ensure that participants from
each interface clinic have an equal chance of receiving
any of the interventions:
 US-guided subacromial corticosteroid injection and
physiotherapist-led individualised, supervised and
progressed exercise
 US-guided subacromial corticosteroid injection and
advice and exercise leaflet
 Unguided (blind) subacromial corticosteroid
injection and physiotherapist-led individualised,
supervised and progressed exercise Unguided (blind) subacromial corticosteroid
injection and advice and exercise leaflet
The injection will be delivered in the same interface
service shoulder clinic. Those randomised to receive the
advice and exercise leaflet will receive this immediately
following their injection. For participants randomised to
receive the physiotherapist-led individualised, supervised
and progressed exercise programme, the trial adminis-
trator will arrange their first physiotherapy appointment
within 3 weeks of the shoulder injection, thereby meet-
ing recommendations that recommendations that resist-
ance exercise should be avoided for 2 weeks following
steroid injection [4].
An evaluation of the success of Research Nurse blind-
ing procedures will be completed and a procedure for
reporting incidents where blinding has been compro-
mised will be in place, through case report forms.
Interventions
US-guided subacromial corticosteroid injection
Clinicians within the interface service shoulder clinics
will deliver US-guided subacromial injection using a
standard technique. Interface clinicians performing US-
guided injections will comprise three rheumatologists,
three extended scope physiotherapists, one musculoske-
letal sonographer, one GPwSI, and one senior rheumato-
logy nurse. Ultrasound examinations will be performed
using the LOGIQe system with a 12 MHz transducer.
The skin and transducer will be cleaned with chlorhexi-
dine 0.5% solution and sterile gel will be applied to the
transducer. The participant will be seated with the shoul-
der internally rotated and the ipsilateral hand placed on
the buttock to allow greatest access to the subacromial
bursa. The transducer will be placed anterolaterally and
the hypoechoic subacromial bursa visualised. A 21G nee-
dle will be inserted under real-time US control until the
needle-tip is seen to enter the bursa. A commercially avail-
able pre-mixed solution of methylprednisolone 40 mg and
1% lidocaine 1 ml will be injected in accordance with re-
cent best-practice recommendations [4].
Unguided (blind) subacromial corticosteroid injection
Different interface clinicians to those providing the
US-guided subacromial injections will deliver unguided
(blind) subacromial injection using a standard technique.
Unguided (blind) injectors will comprise two rheumatolo-
gists, one rehabilitation medicine specialist, four extended
scope physiotherapists and a GPwSI. The participant will
be seated with their arms hanging their by sides with
elbow bent and forearm resting on lap. The skin will be
cleaned with chlorhexidine solution 0.5%. A 21G needle
will be inserted through the deltoid under the acromium
process laterally and the same pre-mixed solution of
Table 1 Content of trial questionnaires
Item Baseline 6 weeks 6 months 12 months
Shoulder problem
Shoulder pain severity today (0-10 NRS) X X X X
Global change [20] X X X
Potential adverse events X
Side of shoulder problem (right, left, both) X
Duration of shoulder problem X
History of previous shoulder problems X
Handedness (right or left) X
Shoulder Pain and Disability Index (SPADI) [32] X X X X
Effect of shoulder disability on typical everyday activities X X X X
Shoulder pain at night [33] X X X X
Psychological factors
Brief illness perception questionnaire [34] X X X X
Pain self-efficacy questionnaire [35] X X X X
Tampa scale of kinesophobia [36] X X X X
General health
EURO-QOL (EQ5D) [37] X X X X
MOS-Short Form 12 (SF-12) [38] X X X X
Other health problems
Pain manikin X X X X
Co-morbidities X
Treatment experiences, preferences, expectations
Previous experience of treatment X
Treatment preferences X
Expectations about different treatments X
Exercise adherence X X X
Confidence and satisfaction with treatment
Confidence in treatment X X X
Treatment satisfaction X X X
Health-care utilisation
Consultation in primary and secondary care X X X
Medication use (prescribed and over-the-counter) X X X
Medical investigations X X X
Hospital admission X X X
Effect of shoulder problem on work
Current/most recent job title and nature of work X
Current employment status X X X X
Work status including alteration in hours/duties X
Work absence X X X X
Work performance X X X X
Stanford presenteeism scale (SPS-6) [39] X X X X
Receipt of benefits, if not working X X X X
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be injected.
Participants receiving either US-guided or unguided
(blind) subacromial injection will be advised not to drive
immediately after receiving the injection and to observe
a period of relative rest for the following two weeks,
avoiding pushing or pulling movements with the affected
arm and heavy or repetitive tasks. Protocols for both
US-guided and unguided injection will allow the injec-
tion to be repeated at the discretion of the treating inter-
face clinician in event of partial response. In line with
recommendations, a maximum of 2 injections will be
permitted during follow-up per participant [4], and the
number of injections received will be recorded.
Physiotherapist-led individualised, supervised and
progressed exercise
The individualised, supervised and progressed exercise
programme will be delivered by community-based, mus-
culoskeletal physiotherapists and commenced within 3
weeks of injection. Exercise type, dose and progression
will be individualised, supervised and progressed in 6 to
8 sessions over a 12 to 16 weeks. Based on available
guidelines [4], a survey of local senior clinicians and a
consensus workshop, the programme will consist of sta-
bility and postural correction exercises, general mobility,
therapeutic strengthening and stretching exercises sup-
ported by an individualised and written exercise sheet
that changes over time in line with exercise progression,
using PhysioTools, a computer package. The exercise
programme will comprise three stages and aim to sup-
port the patient back to their specific everyday physical
activities including sporting activities where relevant.
Stage one will include postural correction, scapular
stability control and proprioceptive exercises. Stage two
will progress to range of movement exercises with sca-
pular control in pain-free range, including for example
shoulder joint forward flexion, abduction and rotation
with progression from assisted to full active exercise. In
stage two, stretches will be added if required and resist-
ance muscle strengthening commenced. Stage three will
progress the resistance through range to encourage rota-
tor cuff muscle strengthening through all ranges of
movement including overhead activity, adding resistance
through the use of Theraband (elastic exercise bands)
and simple weights. Therapists will encourage exercisebehaviour using approaches such as self-monitoring and
goal setting. These plans meet recommendations [4] that
resistance exercise should be avoided for 2 weeks follow-
ing steroid injection.
Participants who fail to attend for any physiotherapy
appointment will be offered up to two further appoint-
ments. After failing to attend the third appointment, no
further appointments will be offered.
Attendance at the physiotherapy-led individualised, su-
pervised and progressed exercise sessions will be moni-
tored, and all non-attended sessions will be recorded on
the appropriate case report form. The frequency and du-
ration of home exercise will be assessed in self-complete
follow-up questionnaires.
Advice and exercise leaflet
Clinicians in the interface service shoulder clinics will
provide the advice and exercise leaflet following the in-
jection. The leaflet includes information about shoulder
anatomy and SIS, plus simple self-help messages about
pain relief (including the application of cold packs) and
activities. It includes a small number of standardised exer-
cises, including specific muscle strengthening and range
of motion exercises [4]. Exercises are not individualised,
supervised or progressed by physiotherapists.
Training of participating interface clinicians and
physiotherapists
Prior to recruitment of participants into the trial, all
interface clinicians and physiotherapists delivering treat-
ment will be trained to deliver the trial interventions ac-
cording to the trial intervention protocols and to record
the interventions on standardised case report forms.
Interface clinicians will attend a half-day group train-
ing session prior to the study commencing which will in-
clude training regarding study procedures, eligibility
assessment, protocols for US-guided or blind injections,
and the delivery of the advice and exercise leaflet. Further
refresher sessions will be provided during the course of
the trial.
Interface clinicians performing blind (unguided) injec-
tions will have extensive clinical experience performing
subacromial injections. Since musculoskeletal ultrasound
is highly operator-dependent and relies on robust train-
ing with direct supervision to gain clinical competency,
interface clinicians performing US-guided injections will
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guided injections or be required to complete a Consor-
tium for the Accreditation of Sonographic Education
(CASE) [40] accredited course with focus on US-guided
subacromial injections. Furthermore, all US-guided in-
jectors will be required to pass the same tests of clinical
competency in US-guided subacromial injections as-
sessed by a Consultant Musculoskeletal Sonographer prior
to commencement of the study.
Physiotherapists will attend a two-day group training
session prior to the trial commencing which will cover
information regarding trial procedures, anatomy and phy-
siology relevant to SIS, current best practice guidelines
[4], treatment options, and the detailed protocol for in-
dividualising, supervising and progressing exercises. A
written manual of instructions on how to deliver the
interventions will be given to each physiotherapist. Fur-
ther refresher sessions will be provided during the course
of the trial.
Treatment sessions will be audited at regular intervals
throughout the trial through case report forms com-
pleted by both interface clinicians and physiotherapists
at clinic, case-note reviews and observation of physio-
therapy sessions by a member of the research team to
ensure the interventions are delivered in accordance
with the intervention protocols. Video recordings of US-
guided injections will be taken throughout the study for
audit and training purposes.
Potential (serious) adverse events
The occurrence of all potential adverse events from all
interventions will be monitored and assessed, using case
report forms, contact with the trial co-ordinator, family
practitioner report, and follow-up questionnaires. If pa-
tients suspect that they have suffered an adverse event
as a result of any of the trial interventions, they will be
asked to notify the trial co-ordinator by telephone, and
to seek medical advice from their family practitioner. In
our letter informing participants’ family practitioners of
trial participation, we will ask the family practitioner to
notify the trial co-ordinator if their patient sustains
either an adverse or serious adverse event as a result
of this trial.
There are usually very few side-effects from cortico-
steroid injections, delivered either unguided (blind) or
with the use of US-guidance. [14,20,27-29]. The interface
clinician performing the injection will advise the patient
how to manage any potential symptoms due to potential
adverse events.
A common adverse event from the exercise regime is
expected to be symptoms of temporary, mild soreness of
the shoulder joint or upper limb. Participants randomised
to the physiotherapist-delivered exercise programme will
be advised how to manage such symptoms by the treatingphysiotherapist. Participants randomised to receive the
Advice and Exercise Leaflet will be able to find similar in-
formation in the leaflet.
Follow-up
Outcome measures will be collected before randomisa-
tion and at 1 week, 6 weeks, 6 months and 12 months
(Table 1).
Participants will be contacted by a research nurse
blind to treatment allocation 1 week after randomisation
by text-message or telephone according to patient pref-
erence. Participants will be asked whether they still have
shoulder pain (yes/no) and to rate their current shoulder
pain intensity (0-10 numeric rating scale (NRS)). Non-
responders to the initial text-message/telephone call will
be contacted again 24 hours later. Those who do not re-
spond to this reminder will be contacted by telephone a
further 24 hours later. Data will be transposed by the re-
search nurse onto a standard case report form.
Outcome at 6 weeks, 6 months and 12 months will
be collected by postal questionnaire (Table 1). Non-
responders to follow-up questionnaires will be sent a
reminder postcard after two weeks. Those who do not re-
spond to the reminder postcard will be sent a repeat ques-
tionnaire and Participant Information Sheet with a further
covering letter four weeks after the initial mailing. Non-
responders to the repeat questionnaire will be telephoned
by the Research Nurse (who will remain blind to group al-
location), in order to try to capture key primary outcome
data and to minimise missing data. A postal minimum
data collection form will be mailed to the participant if the
participant has not been contacted after 5 phone-call at-
tempts or if 2 weeks have lapsed from the mail-out of the
reminder letter and follow-up questionnaire.
Outcome measures
Content of trial questionnaires is shown in Table 1. The
primary outcome measure is the Shoulder Pain and Dis-
ability Index (SPADI) [32]. Secondary outcomes include
current shoulder pain intensity (0-10 NRS), patient’s self-
reported global impression of change [20], general health
[38], sleep [33], pain self-efficacy [35], fear-avoidance [36],
return to desired activities including work and social life,
work performance [39], healthcare utilisation (medica-
tions, visits to healthcare practitioners, further injections
or physiotherapy), health status [37], treatment prefer-
ences and expectations, illness perceptions [34], exercise
adherence and satisfaction with treatment. Potential ad-
verse events from all interventions will be monitored.
Sample size
The trial is powered, at the 80% level, to detect a ‘small’
to ‘moderate’ effect size (standardised mean difference,
0.4) in shoulder pain and disability (SPADI) for the two
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individualised, progressed and supervised exercise versus
standardised advice and exercise leaflet). To address
whether the physiotherapy-led intervention consisting of
individualised, supervised and progressed exercise pro-
vides better improvements in pain and function than a
standardised advice and exercise leaflet, we will use the
total SPADI score at the 6 month time-point, as the pri-
mary outcome measure. Since previous trials have
shown that corticosteroid injections improve pain and
function more rapidly than exercise [14,20,21], we will
use the total SPADI score at the 6 week time-point as
the primary outcome measure for the comparison of
US-guided and unguided (blind) injection.
A total sample size of 250 participants is needed given
80% power; 5% two-tailed significance; and assuming
20% loss to follow up.
Analysis
The primary intention-to-treat (ITT) analysis will be
double-analysed independently by two blinded statisti-
cians. Between-group analysis will be undertaken ac-
cording to randomised allocation with retention of all
participants throughout follow up for the purposes of full
evaluation. The primary evaluations will be mean differ-
ences in total SPADI scores at 6 weeks between those ran-
domised to receive US-guided injection versus unguided
injection, and mean differences in total SPADI scores at 6
months between those randomised to physiotherapist-led
individualised, supervised and progressed exercise versus
advice and exercise leaflet. Secondary analyses will include
comparison of pain and disability subscales of the SPADI;
long-term SPADI outcomes (i.e. at 12 months); and ana-
lysis of other outcome measures. Estimates of clinical
effect of the two main comparisons will be shown as
percentage differences (for dichotomous outcomes) and
mean differences (for numerical outcomes), with 95% con-
fidence intervals. P-values will be given alongside statis-
tical testing of the data. Multilevel longitudinal (mixed-)
model regression methods (linear for numerical outcomes
and logistic for dichotomous outcomes) will be used to
generate estimates of effects. By including the baseline
values as outcome the model retains all available data (as
opposed to complete-case data only) and upholds the full
intention-to-treat analytic criterion. An assumption of this
approach is that the missing data is missing at random
(MAR) – being dependent on baseline factors utilised in
the model. Covariates included in the regression models
are as follows: age, gender, baseline SPADI scores, dur-
ation of pain and location of clinic. Sensitivity analyses will
include any other variables which are unbalanced between
the groups at baseline.
Primary interest focuses on main effects (‘at the mar-
gins’) evaluation as our assumption is that the twointerventions will act largely independently of each other.
As a secondary analysis, we will estimate the interaction
effect from a separate regression model (inclusive of inter-
action term) since any potential synergistic/antagonistic
effect of the combination of treatments should be repor-
ted [41]. Descriptively, we will also present mean SPADI
scores (95% CIs) for each of the four treatment groups. A
sizeable interaction (contrary to expectation) would imply
that findings based on an analysis of main effects alone
are not sufficient as an effect of combined treatments may
exist and should be considered alongside policy recom-
mendations for the two treatments.
A per protocol analysis (analysing only those patients
who received the interventions in line with trial proto-
col) will be carried out as a sensitivity analysis.Economic evaluation
Economic evaluation will estimate the cost-effectiveness
of the trial interventions. A cost-consequence analysis
will initially be reported, describing all the important re-
sults relating to costs and consequences in the interven-
tion arms over the 12-month trial period. Subsequently,
an incremental cost-utility analysis will be undertaken
using patient responses to the EQ-5D-5L, to calculate
the cost per additional Quality-Adjusted Life Year (QALY)
gained over the same period. The analysis will adopt a
broad perspective, considering NHS, patient and product-
ivity costs. Data on health care resource use and time off
work over 12 months follow-up will be obtained from the
patient questionnaires. The resource use questions will
capture details covering a broad range of health care re-
sources, including prescribed and over-the-counter pur-
chased medications, primary care and secondary care
(inpatient and outpatient) attendances, treatments and
investigations. Unit costs will be obtained from stand-
ard sources and health care providers, including NHS
reference costs and the British National Formulary. Owing
to the paucity of high-quality unit cost data for private
health care consultations, these data will be costed as the
NHS equivalent. Indirect costs, over 12 months follow-up,
will be based on productivity losses due to work incapacity
linked to presenteeism, and also work absenteeism. Costs
for productivity loss will be computed through the pro-
duct of lost productivity time (whether presenteeism
and/or absenteeism) and the mean hourly wage of pa-
tients classified from data on wages corresponding to self-
reported baseline occupation (derived from the Annual
Surveys of Health Evaluation by the Office of National
Statistics and based on classification codes under the UK
Socio-Economic Occupation Classification, SOC 2000)
QALYs will be calculated using the EQ-5D 5L index
scores at baseline, 6 weeks, 6 months and 12 months,
using the area-under-the-curve method.
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http://www.biomedcentral.com/1471-2474/15/81There is no consensus regarding how economic eval-
uations should be carried out alongside factorial trials
and previously published economic evaluations along-
side factorial trials have used two main methods: the
‘within the table’ approach [42] and the ‘at the margins’
approach [43]. The base-case economic analysis here will
use the ‘at the margins’ approach and follow the primary
objectives of the clinical trial. Therefore two separate
analyses will be undertaken to consider (1) the physio-
therapist–led exercise intervention versus a standardised
advice and exercise leaflet and (2) US-guided subacromial
injection versus blind injection. Two secondary analyses
will also be undertaken. The first will mirror the secon-
dary analysis of the trial and using regression modelling,
explore the impact on the results of inclusion of an inter-
action term. The second will conduct a ‘within the table’
analysis and consider all four treatment options. This me-
thod requires interventions to be ordered in terms of
increasing cost, and cost and outcomes for each interven-
tion are compared incrementally. The most cost-effective
option will be selected based on the principles of simple
(strong) dominance (where an intervention is less costly
and more effective) and extended (weak) dominance
(where an intervention is ruled out if the ICER is greater
than that of a more effective intervention).
Missing cost and utility data will be imputed using
multiple imputation through chained equations, with the
number of imputation datasets set to reflect the propor-
tion of missingness in the data as recommended by pre-
vious guidelines into the use of MI approaches [44]. All
analyses will be adjusted for baseline EQ-5D 5L score.
The comparison results will be presented using cost-
effectiveness planes and cost-effectiveness acceptability
curves, generated using bootstrap techniques, to reflect
sampling variation. Sensitivity analyses (both simple and
probabilistic) will be conducted as necessary to explore
the importance of key uncertainties in any assumptions
made in the base case analysis.
Discussion
The SUPPORT trial will compare the clinical and cost-
effectiveness of (1) US-guided corticosteroid injection
to unguided (blind) corticosteroid injection and (2) a
physiotherapist-delivered individualised, supervised and
progressed exercise programme to provision of a standar-
dised advice and exercise leaflet, for treatment of patients
with SIS. In comparison to existing trials of injection
and exercise interventions for SIS, the strengths of the
SUPPORT trial are its size, long-term follow-up and inclu-
sion of an individualised, supervised and progressed exer-
cise programme which builds upon existing guidelines [4]
to optimise treatment outcome [12-15] and inclusion of a
cost-effectiveness analysis. The main limitation, common
to many trials of non-pharmacological interventions, isthe inability to blind participants to treatment allocation.
Whilst existing trials suggest some efficacy of both cor-
ticosteroid injections and exercises to treat SIS [10,16], the
findings of the SUPPORT trial will inform clinical practice
about optimal delivery of these interventions to improve
pain and function in primary care and at the primary-
secondary care interface.
Abbreviations
GP: General practitioner; GPwSI: General practitioner with a special interest;
MSUS: Musculoskeletal ultrasound; NHS: National Health Service; NRS:
Numeric rating scale; SIS: Subacromial impingement syndrome; US-guided:
Ultrasound-guided.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
All authors participated in the design of the trial and the drafting of the
manuscript. All authors have read and approved the final manuscript.
Acknowledgements
This paper presents independent research funded by the Arthritis
ResearchUK Centre in Primary Care grant (Grant Number 18139) and by the
National Institute for Health Research (NIHR) under its Research for Patient
Benefit programme (Grant Reference Number PB-PG-1207-15064) and an
NIHR Research Professorship for NE Foster (NIHR-RP-011-015). The views
expressed are those of the authors and not necessarily those of the NHS, the
NIHR or the Department of Health. Funding was also secured by the North
Staffordshire Primary Care Research Consortium for NHS and service
support costs.
The authors would like to acknowledge Kris Clarkson, Treena Larkin, Debbie
Cook, and Sue Weir and the administrative and research nurse teams from
the Arthritis Research UK Primary Care Centre. We would also like to thank
the clinicians and administrative staff of Staffordshire and Stoke-on-Trent
Partnership NHS Trust.
SUPPORT trial team: Praveen Datta, Alison Hall, Sue Jackson, Julie
Shufflebotham, Julie Young.
Author details
1Arthritis Research UK Primary Care Centre, Research Institute for Primary
Care and Health Sciences, Keele University, Keele, Staffordshire ST5 5BG, UK.
2Staffordshire Rheumatology Centre, Haywood Hospital, High Lane, Burslem,
Stoke-on-Trent ST6 7AG, UK. 3Physiotherapy Department, University Hospital
of North Staffordshire, Stoke-on-Trent, UK.
Received: 3 March 2014 Accepted: 10 March 2014
Published: 14 March 2014
References
1. Chard M, Hazleman R, Hazleman BL, King RH, Reiss BB: Shoulder disorders
in the elderly: a community survey. Arthritis Rheum 1991, 34:766–769.
2. Picavet HS, Schouten JS: Musculoskeletal pain in the Netherlands:
prevalences, consequences and risk groups, the DMC(3)-study. Pain 2003,
102:167–178.
3. van der Windt DA, Koes BW, de Jong BA, Bouter LM: Shoulder disorders in
general practice: incidence, patient characteristics and management.
Ann Rheum Dis 1995, 54:959–964.
4. Hanchard N, Cummins J, Jeffries J: Evidence-Based Clinical Guidelines for the
Diagnosis, Assessment and Physiotherapy Management of Shoulder
Impingement Syndrome. London: Chartered Society of Physiotherapy; 2004.
5. Bigliani LU, Levine WN: Subacromial impingement syndrome. J Bone Joint
Surg 1997, 79:1854–1868.
6. Map of Medicine: Subacromial pain. [http://healthguides.mapofmedicine.
com/choices/map/shoulder_pain7.html]
7. Roddy E, Zwierska I, Jordan KP, Dawes P, Hider SL, Packham J, Stevenson K,
Hay EM: Musculoskeletal clinical and assessment treatment services at
the primary-secondary care interface: an observational study. Br J Gen
Pract 2013, 63:e141–e148.
Roddy et al. BMC Musculoskeletal Disorders 2014, 15:81 Page 10 of 10
http://www.biomedcentral.com/1471-2474/15/818. Kibler WB, McMullen J, Uhl T: Shoulder rehabilitation strategies, guidelines
and practice. Orthop Clin N Am 2001, 32:527–538.
9. Walther M, Werner A, Stahlschmidt T, Woelfel R, Gohlke F: The subacromial
impingement syndrome of the shoulder treated by conventional
physiotherapy, self-training, and a shoulder brace: results of a prospective,
randomized study. J Shoulder Elbow Surg 2004, 13:417–423.
10. Hanratty CE, McVeigh JG, Kerr DP, Basford JR, Finch MB, Pendelton MB,
Sim J: The effectiveness of physiotherapy exercises in subacromial
impingement syndrome: a systematic review and meta-analysis. Semin
Arthritis Rheum 2012, 42:297–316.
11. Gebremariam L, Hay EM, van der Sande R, Rinkel WD, Koes BW, Huisstede
BM: Subacromial impingement syndrome – effectiveness of
physiotherapy and manual therapy. Br J Sports Med 2013. doi:10.1136/
bjsports-2012-091802. [Epub ahead of print].
12. Hayden JA, van Tulder MW, Tomlinson G: Systematic review: strategies for
using exercise therapy to improve outcomes in chronic low back pain.
Ann Intern Med 2005, 142:776–785.
13. Engebretsen K, Grotle M, Bautz-Holter E, Sandvik J, Juel NG, Ekeberg OM,
Brox JL: Radial extracorporeal shockwave treatment compared with
supervised exercises in patients with subacromial pain syndrome: single
blind randomised study. BMJ 2009, 339:b3360.
14. Crawshaw DP, Helliwell PS, Hensor EM, Hay EM, Aldous SJ, Conaghan PG:
Exercise therapy after corticosteroid injection for moderate to severe
shoulder pain: large pragmatic randomised trial. BMJ 2010, 340:c3037.
15. Holmgren T, Bjornsson Hellgren H, Oberg B, Adolfsson L, Johansson K:
Effect of specific exercise strategy on need for surgery in patients with
subacromial impingement syndrome: randomised controlled study. BMJ
2012, 344:e787.
16. Buchbinder R, Green S, Youd JM: Corticosteroid injections for shoulder
pain. Cochrane Database Syst Rev 2003, 1:CD004016. CD004016.
17. Hay EM, Thomas E, Paterson SM, Dziedzic K, Croft PR: A pragmatic
randomised controlled trial of local corticosteroid injection &
physiotherapy for the treatment of unilateral shoulder pain in primary
care. Ann Rheum Dis 2003, 62:394–399.
18. Ginn KA, Cohen ML: Exercise therapy for shoulder pain aimed at
restoring neuromuscular control: a randomized comparative clinical trial.
J Rehabil Med 2005, 37:115–122.
19. Johansson K, Bergstrom A, Schroder K, Foldevi M: Subacromial
corticosteroid injection or acupuncture with home exercises when
treating patients with subacromial impingement in primary care – a
randomized clinical trial. Fam Pract 2011, 38:355–365.
20. van der Windt DA, Koes BW, Deville W, Boeke AJ, de Jong BA, Bouter LM:
Effectiveness of corticosteroid injection versus physiotherapy for
treatment of painful stiff shoulder in primary care: randomised trial. BMJ
1998, 317:192–196.
21. Winters JC, Jorritsma W, Groenier KH, Sobel JS, Meyboom-de Jong B,
Arendzen HJ: Treatment of shoulder complaints in general practice: long
term results of a randomised single-blind study comparing physiotherapy,
manipulation and corticosteroid injection. BMJ 1999, 318:1395–1396.
22. Partington PF, Broome GH: Diagnostic injection around the shoulder: hit
and miss? A cadaveric study of injection accuracy. J Shoulder Elbow Surg
1998, 7:147–150.
23. Yamakado K: The targeting accuracy of subacromial injection to the
shoulder: an arthrographic evaluation. Arthroscopy 2002, 18:887–891.
24. Rutten MJ, Maresch BJ, Jager JG, de Waal Malefijit MC: Injection of the
subacromial-subdeltoid bursa: blind or ultrasound-guided? Acta Orthop
2007, 78:254–257.
25. Grassi W, Filippucci E, Busilacchi P: Musculoskeletal ultrasound. Best Pract
Res Clin Rheumatol 2004, 18:813–826.
26. Nazarian LN: The top 10 reasons musculoskeletal sonography is an
important complementary or alternative technique to MRI. Am J
Roentgenol 2008, 190:1621–1626.
27. Ekeberg OM, Bautz-Holter E, Tveita EK, Juel NG, Kvalheim S, Brox JL:
Subacromial ultrasound guided or systemic steroid injection for rotator
cuff disease: a randomised double blind study. BMJ 2009, 338:a3112.
28. Naredo E, Cabero F, Beneyto P, Cruz A, Modejar B, Uson P, Palop MJ, Crespo
M: A randomized comparative study of short term response to blind
injection versus sonographic-guided injection of local corticosteroids in
patients with painful shoulder. J Rheumatol 2004, 31:308–314.
29. Ucuncu F, Capkin E, Karkucak M, Ozden G, Cakirbay H, Tosun M, Guler M:
A comparison of the effectiveness of landmark-guided injections andultrasonography guided injections for shoulder pain. Clin J Pain 2009,
25:786–789.
30. Sage W, Pickup L, Smith TO, Denton ER, Toms AP: The clinical and
functional outcomes of ultrasound-guided vs landmark-guided injections
for adults with shoulder pathology – a systemic review and meta-
analysis. Rheumatology (Oxford) 2013, 52:743–751.
31. Chen MJ, Lew HL, Hsu TC, Tsai WC, Lin WC, Tang SF, Lee YC, Hsu RC,
Chen CP: Ultrasound-guided shoulder injections in the treatment of
subacromial bursitis. Am J Phys Med Rehabil 2006, 85:31–35.
32. Roach KE, Budiman-Mak E, Songsiridej N, Lertratanakul Y: Development of a
shoulder pain & disability index. Arthrit Care Res 1991, 4:143–149.
33. Dawson J, Fitzpatrick R, Carr A: Questionnaire on the perceptions of
patients about shoulder surgery. J Bone Joint Surg Br 1996, 78:593–600.
34. Broadbent E, Petrie KJ, Main J, Weinmann J: The brief illness perception
questionnaire. J Psychosom Res 2006, 60:631–637.
35. Nicholas MK: The pain self-efficacy questionnaire: taking pain into
account. Eur J Pain 2007, 11:153–163.
36. Woby SR, Roach NK, Urmston M, Watson PJ: Psychometric properties of
the TSK-11: a shortened version of the Tampa Scale for Kinesiophobia.
Pain 2005, 117:137–144.
37. The EuroQol Group: EuroQol - a new facility for the measurement of
health-related quality of life. Health Policy 1990, 16:199–208.
38. Brazier JE, Roberts J: The estimation of a preference-based measure of
health from the SF-12. Med Care 2004, 42:851–859.
39. Koopman C, Pelletier KR, Murray JF, Sharda CE, Berger ML, Turpin RS,
Hackleman P, Gibson P, Holmes DM, Bendel T: Stanford presenteeism
scale: health status and employee productivity. J Occup Environ Med 2002,
44:14–20.
40. Consortium for the accreditation of sonographic education. [http://www.
case-uk.org/]
41. Montgomery AA, Peters TJ, Little P: Design, analysis and presentation of
factorial randomised controlled trials. BMC Med Res Methodol 2003, 3:26.
42. Pinto D, Robertson MC, Abbott JH, Hansen P, Campbell AJ, the MOA Trial
Team: Manual therapy, exercise therapy, or both, in addition to usual
care, for osteoarthritis of the hip or knee.2: economic evaluation
alongside a randomised controlled trial. Osteoarthritis Cartilage 2013,
21:1504–1513.
43. Dangour AD, Albala C, Allen E, Grundy E, Walker DG, Aedo C, Sanchez H,
Fletcher O, Elbourne D, Uauy R: Effect of a nutrition supplement and
physical activity program on pneumonia and walking capacity in
Chilean older people: a factorial cluster randomized trial. PLoS Med 2011,
8:e1001023.
44. White IR, Royston P, Wood AM: Multiple imputation using chained
equations: issues and guidance for practice. Stat Med 2011, 30:377–399.
doi:10.1186/1471-2474-15-81
Cite this article as: Roddy et al.: Subacromial impingement syndrome
and pain: protocol for a randomised controlled trial of exercise and
corticosteroid injection (the SUPPORT trial). BMC Musculoskeletal Disorders
2014 15:81.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
